Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price fell 0.4% during mid-day trading on Friday after BMO Capital Markets lowered their price target on the stock from $160.00 to $156.00. BMO ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in ...

We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...